PepGen has ended clinical trials of PGN-EDO51, their investigational therapy for Duchenne patients amenable to skipping exon 51, as PGN-EDO51 failed to achieve target dystrophin levels in their CONNECT1 trial.
The company intends to wind down all DMD-related research and development activities. While it is a disappointing outcome, we’d like to thank PepGen, who CureDuchenne provided early funding to, for their work developing PGN-EDO51 and trying to improve the lives of individuals with Duchenne. We would also like to thank everyone in the community who participated in these studies. More information can be found here.
See the attached letter to the community
The post PepGen ends development of Duchenne Exon-51 skipping program appeared first on CureDuchenne.